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Summary
The Ipr gene in homozygous form induces development of CD4 - CD8-B220+ T cells and
lymphadenopathy in MRL and C57BL/6 mice. Although the propensity for excessive production
ofT cells is related to an intrinsic T cell defect, a thymus is also required because neonatal thymectomy
eliminates lymphadenopathy. Recent evidence suggests that excessive production and release of
autoreactive T cells from the thymus of lpr/lpr mice might lead to downregulation of CD4 and
CD8 as a "fail safe" tolerance mechanism that occurs during late thymic or post-thymic development.
To test this hypothesis, T cell receptor (TCR) transgenic mice that produce large numbers of
immature thymocytes recognizing the H-2Db and male H-Y antigens were backcrossed with
C57BL/6-lpr/lpr mice and MRIrlpr/lpr mice. It was predicted that Db male lpr/lpr mice would
produce large numbers of autoreactive T cells during early thymic development that would lead
to an accelerated lymphoproliferative disease. In contrast, Db female lpr/lpr mice would produce
large numbers of Db H-Y-reactive T cells, but might not develop lymphadenopathy because the
male HY antigen would not be present. Unexpectedly, there was complete elimination of
lymphadenopathy in both male and female TCR transgenic lpr/lpr mice. The elimination of
lymphadenopathy was not due to a failure of thymic maturation since the thymus of H-2Db
female lpr/lpr mice contained nearly normal numbers of mature thymocytes. Elimination of
lymphadenopathy was also not due to a lack of autoreactive T cells in the peripheral lymph
nodes (LN) since there was an increased syngeneic mixed lymphocyte proliferative response of
LN T cells from transgenic lpr/lpr compared with +/+ mice in vitro. Hypergammaglobulinemia
and autoantibody production in the transgenic lpr/lpr was present at levels comparable with or
higher than control nontransgenic lpr/lpr mice, suggesting a dissociation of autoantibody production
from the lymphoproliferative disease in the TCR transgenic mice. Conversely, the development
of lymphadenopathy and production of CD4 - CD8 - B220+ T cells appear to be intimately
linked, as both were completelyeliminated in T cells expressing the transgenic TCR. We propose
that lymphoproliferation and production of CD4 - CD8 - 6B2+ T cells in lpr/lpr mice is related
to decreased expression of the TCR, and providing the T cellswith a rearranged TCR transgene
overcomes this defect.
MRlrlpr/lpr mice have been used as a model for human
,j,~/~ autoimmune disease because they develop hypergam-
maglobulinemia, anti-DNA, anti-Sm, RF, and circulating
immune complexes, as well as arthritis and glomerulonephritis
(1-4). A striking feature of this autoimmune disease is the
development of peripheral lymphadenopathy due to the ex-
pansion of an unusual T cell subset that expresses the pheno-
type Thy-1+, dull Ly-1, CD4- , CD8- , 9F3+, B220+,
F23.1+, and IIr2R (5-7). Only 5% of peripheral LN T cells
from Ipr/Ipr mice are cycling, suggesting that increased prolifer-
ation does not totally account for the lymphadenopathy (8).
During the first 2 wk of life, thymectomy reduces the dis-
ease, suggesting that excess numbers of abnormal cells leave
the thymus and seed the periphery during this time (9, 10) .
However, there does not appear to be a global defect in thymic
tolerance induction because clonal deletion of certain self-
reactive (Mls, I-E reactive) T cells has been observed in lpr/lpr
mice (11-13).
The present experiments were designed to directly study
if overproduction of self-reactive T cellsin the thymus leads
1805
￿
J. Exp. Med. ® The Rockefeller University Press " 0022-1007/90/12/1805/13 $2.00
Volume 172 December 1990 1805-1817to development of lymphadenopathy and excess numbers of
CD4 -CDS-11220+ LN T cells. To address this question,
MRLlpr/lprand C57BL/6-lpr/lpr mice were backcrossed to
a transgenic mouse expressing a TCR specific for the male
H-Y antigen presented in association with MHC H-21)6
(14-16). The rationale for usingthis transgenic mouse is that
it allows for production of essentially a monoclonal popula-
tion ofthymocyte precursor cells that are autoreactive in male
but not female mice. The nonautoimmune transgenic mouse
expressing the Db-restricted anti-HY TCR has been used
as a model for the study of positive and negative selection
in the thymus ofnormal mice (17, 18). The transgenic TCR
uses the V08.2 TCR gene product which can be identified
using an antiV#8 or anticlonotypic antibody, and therefore
could easily be studied during thymic development by flow
rytometry analysis (17). Previously, it has been shown that
interaction of CD4+8+ thymocytes with H-2D6 molecules
on thymic epithelial cells results in positive selection of
CD8+ T cells expressing both the a and /3 chain of the
transgenic TCR. Transgenic female mice do not produce
the HY antigen, and therefore, the CD8+ T cells expressing
the transgenic TCR are not self-reactive and are not subjected
to a negative selection process. Transgenic malesproduce the
H-Y antigen and the autoreactive CD8+ T cells lose the
ability to be stimulated by the HY antigen by downregula-
tion of CD8 (14-16). Although nearly all thymocytes ex-
press the transgenic /3 chain, some thymocytes express the
endogenous TCR a chain. Interaction of CD4+8+ thymo-
cytes that rearrange and express the endogenous TCRa chain
mature into CD4+ thymocytes (15) or fail to undergo posi-
tive selection and die in the thymus (16) .
The breeding of the transgenic mouse with MRlrlpr/lpr
mice resulted in 16 genetically distinct groups o£mice (differing
in transgene, lpr gene, sex, and MHC) for analysis. The most
dramatic effect of the TCR transgene was the complete in-
hibition of lymphadenopathy and production of CD4-
CD8-B220+ LN T cells in TCR transgenic mice homozy-
gous for the lpr/lpr gene. This occurred in both male and
female mice and occurred in H-2Dbib, H-2Dbik, and
H-2Dkik transgenic mice. There were no detectable CD4-
CD8 -B220+ T cells in the LN of transgenic lpr/lpr mice,
while nontransgenic lpr/lpr litter matesdeveloped massive ac-
cumulation of these abnormal T cells as expected for lpr/lpr
mice. The combined effect of the TCR transgene and lpr/lpr
gene provides new insights into the nature of the lym-
phoproliferation disease in lpr/lpr mice.
Materials and Methods
Animals.
￿
The TCR transgenic male mice carrying the rear-
ranged TCR a and 0 chains were produced as previouslydescribed
(14-16). The original breeding pairs of MRL1pr/lpr, MRL +/+
mice, C57BL/6-lpr/lpr, and C57BL/6 +/+ mice were obtained
from The Jackson Laboratory (Bar Harbor, ME).
Isolation o,f Tail DNA.
￿
A 1-cm section of tail from 4-wk-old
mice was first minced into fine pieces, and then crushed by 10 strokes
of a glass Dounce homogenizer in 0.9 cc of TEN buffer (50 mM
Tris, pH 7.4, 50 mM EDTA, 100 mM NaCl). After addition of
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50 pl ofproteinaseK (100 wg/ml final concentration) (Boehringer
Mannheim Biochemicals, Indianapolis, IN) and 50 /Alof10% SDS,
the sample was incubated at 50°C for 18 h with gentle rocking.
If the sample was adequately digested, boiled RNase A (100 FAg/ml
final concentration) (Boehringer Mannheim Biochemicals) was
added and the sample was then incubated at 37°C for an additional
2 h. The DNA was gently extracted with phenol (pH 7),
phenol/chloroform (1:1 vol/vol), and chloroform. After each ex-
traction, the sample was centrifuged for 10 min in a microcen-
trifuge and the supemate transferred using a pipette with a cut
tip. After addition of 2 vol ofethanol and gentle mixing, the DNA
wasprecipitated bycentrifugation for 10 min at high speed, washed
with 70% ethanol, and dried in a speed vac. The dried DNA was
resuspended in 50 ul of TE (10 mM Tris, pH 7.4, 1 mM EDTA).
The procedure yields 20-100 wg of DNA.
Southern Blots.
￿
Southern blotswere prepared as previouslyde-
scribed (7) by digestion of 10 pg of DNA with PvuII restriction
endonuclease, electrophoresis, and blotting. Membranes (Nitroplus
2000; Micron Separations, Inc., Westboro, MA) were baked for
2 h at 80°C in a vacuum oven. Membranes were prehybridized
and then hybridized with 1-3 x 106 cpm/ml of hybridization so-
lution containing different DNA probes that had been labeled with
32P-dCTP by random priming (19) to a specific activity of 109
cpm/hg. Filters were then washed with 2x SSC + 0.1% SDS
at room temperature for 30 min, with 2x SSC + 0.1% SDS at
42°C for 30 min, and then with 0.1x SSC + 0.1% SDS at 60°C
for 30 min; theywere then exposed to Kodak XAR-2 film (Eastman
Kodak Co., Rochester, NY) at -70°C with intensifying screens
for 4 d.
DNA Probes.
￿
Vtx3 was the 0.42-kb Scal/Xhol fragment from
the HYa3 cDNA clone MnTTa1.35 previously described (17, 18)
and J#2 was the 2.0-kb EcoRI fragment of pUC8J#2B generously
provided by Leroy Hood (California Institute of Technology,
Pasadena, CA) (20).
Antibodies.
￿
Biotinylated antiThyl.2 was obtained from Becton
Dickinson & Co. (Mountain View, CA). Anti-CD4 (clone GK1.5)
and anti-CD8 (clone 53-6.7) were obtained from American Type
Culture Collection (Rockville, MD). Anti-I-A k (clone 10-3.6.2)
and anti-IA' (clone D3.137.5) were generously provided by Dr.
R. Eisenberg (University of North Carolina, Chapel Hill, NC).
Anti-V08 (clone F23.1) was obtained from M. Bevan (Scripps
Clinic, La Jolla, CA) (21). Anti-11220 (clone 6112) was obtained
from R.L. Coffman (DNAX Research Institute, Palo Alto, CA)
(22). Anti-CD3 (clone 145-2C11) was obtained from JeffBluestone
(University of Chicago, Chicago, IL) .
Flow Cytometry Analysis.
￿
Single cell suspension ofthymocytes
(106 per sample) were stained in PBS with 5% FCS and 0.1% so-
dium azidewith optimal concentrations of antibodies. Incubations
were for 30 min at 4°C. First-step reagents were biotin-conjugated
anti-CD4 and arsynilic acid (ARS)I-conjugated (23) anti-CD8.
Second-step reagents were a PE-conjugated rat IgG monoclonal
(6.21.G.11) anti-ARS, a Texas red®-PE tandem fluorochrome con-
jugated to streptavidin (Southern Biotechnology Associates, Bir-
mingham, AL), and FITC-conjugated anti-Vo8 mAbs. Viable cells
(10,000 per sample) were analyzed by flow rytometry on a FACS-
Scan (Becton Dickinson & Co.) with logarithmic scales.
Cell Proliferation Assay.
￿
Spleen cells (106) from 10-wk-old mice
were cultured in the presence of20 U/ml IL2 (Amgen Biological,
Thousand Oaks, CA) in 200 p.l total volume. Proliferation was
determined after 5 d by a 6-h pulse of 1 /ACi [3H]thymidine
1 Abbreviations used in this paper: ARS, arsynilic acid; BBS, borate-buffered
saline; NT, nontransgenic; SMLR, syngeneicmixed lymphocyte reaction.
T Cell Receptor Transgene Prevents Lymphadenopathy in lpr/lpr Mice(Amersham Corp., Arlington Heights, IL), and [3H]thymidine
uptake was measured by liquid scintillation counting.
SerumIg Determinations.
￿
Sera was collected by retro-orbitalsinus
puncture from 10-wk-old mice. IgG1 and IgG2a concentrations
were determined by ELISA as previously described (24). Briefly,
96-well microtiter plates were coated with isotype-specific goat
anti-mouse Ig (4 pg/ml) (Southern Biotechnology Associates). The
plates were blocked with borate-buffered saline (BBS;25 mM borate,
140mM NaCl, pH 7.4)containing 1% BSA (Sigma Chemical Co.,
St. Louis, MO). Sera were diluted 100,000-foldwith BBScontaining
1% BSA and assayed afterincubation for 4 h at 22°C. After each
incubation, the plates were washed extensively with BBS. Bound
antibodies were detected with isotype-specific alkaline phospha-
tase-conjugated goat anti-mouse Ig (Southern Biotechnology As-
sociates) using p-nitrophenylphosphate (Sigma Chemical Co.) as
a substrate. Ig isotype standards (Zymed Laboratories, Inc., South
San Francisco, CA) were assayed in each experiment and the absor-
bance at 405nm for sera and standards were determined on a Titertek
Multiskan microplatereader (Flow Laboratories, Inc., McLean, VA).
Rheumatoid Factor and Anti-DNA Determinations.
￿
RF was de-
termined as described above except that the %-well microtiter plates
were coated with affinity-purified rabbit IgG (4 ug/ml; Sigma
Chemical Co.) and sera were initially diluted 200-fold. Bound an-
tibodies were detected with alkaline phosphatase-conjugated isotype-
c goat anti-mouse IgG2a(Southern Biotechnology Associates)
usingp-nitrophenylphosphate (Sigma Chemical Co.) as a substrate.
RF levels were expressed as the absorbance at 405 nm (A4os). Anti
dsDNA antibodies were determined as described above except that
the 96-well microtiter plates were precoated with poly->.-lysine
(Sigma Chemical Co.) and subsequently with dsDNA (Sigma
Chemical Co.). Control poly-L-lysine-precoated wellswere coated
with poly-L-glutamic acid. Sera were initially diluted 200-fold and
bound anti-dsDNA antibodies, expressed as Aos, were determined
as described above for RF.
Results
Unambiguous Identification ofHomozygous lprllpr TCR Trans-
genic Mice. The 1pr (lymphoproliferation) gene is unmapped
and the 1pr gene product is unknown. Therefore, the only
way to identify the presence of the 1pr gene is by observation
of the development of the characteristic lymphadenopathy,
Figure 1.
￿
Mating scheme used to backcross
TCR transgenic mice with lpr/Ipr mice to
produce TCRtransgenic lprllprmice. All mice
Tr- 50% (+/+, Ipr/+) nl LN
￿
from the first backcross (BCI) were heterozy-
gous for the 1pr gene and did not develop
lymphadenopathy, indicated as nl LN in the
figure. Transgenic mice from this generation
(50% ofthemice)werebackcrossed again with
lpr/Iprmice. Although 25% of the offspring
mice should have inherited the transgene and
should also have been homozygous for the 1pr
gene (shown in the rectangular box), none of
the transgenic mice developed lymphadenop-
athy. Apprcovmately 50% ofthe mice from this
mating (BC2)were transgenicand thesemice
weremated in separate cageswith lprllprmice.
Approximately 50% of the offspring were transgenic and 50% were nontransgenic. The nontransgenic mice from this generation (BC3) were evalu-
ated as described in Table 2 for development of lymphadenopathy and 13220+ T cells. If the BC2 parent was heterozygous for the 1pr gene, -50%
of the nontransgenic offspring developed lymphadenopathy, whereas if the BC2 parent was homozygous for the 1pr gene, all of the nontransgenic offspring
of this mating developed lymphadenopathy and 13220+ T cells.
BCC (50% MRL)
￿
Tr+ 50% (Trl+, Iprl+) nl LN
BC2 (75% MRL)
￿
Tr+ 25% (Trl+, prl+) nl LN
Tr-
BC3 (87.5% MRL)
X MRL-Ipr/Ipr
j
25% (+1+, I r/+) nl LN
Tr+ 25% (Trl+, !pr/*) M LN
25% (Trl+, )p pr r/Ipr) nl LN
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[C57BL(Tr/+) X MRL-_Ipr/Ipr] F 1
M LN
￿
Tr-
X MRL-Ipr/Ipr
￿
Tr'
Tr- 50% (+/+, prlpr) f LN
Tr+ 50% (Trl+, Ipr/lpr) nl LN
and an increase in CD4 - CD8 -13220+ T cells in mice that
are homozygous for the 1pr gene (2, 3, 5). In addition, devel-
opment of elevated serum levels of Igs of the IgG1, IgG2a,
IgG2b, and IgG3 isotype occurs by 6 wk of age in lprllpr
mice (4). However, use ofthese phenotypic features to iden-
tify TCR transgenic lprllpr mice might be misleading be-
cause the presence of the transgenic TCR might alter the
phenotypiccharacteristics of lprllpr mice. Therefore, a breeding
scheme was devised that identifiedTCR transgenic mice that
were homozygous for the 1pr gene by analysis of their non-
transgenic ofprings (Fig. 1). TCR transgenic mice were back-
crossed with MRIrlprllpr mice to produce (C57BL x MRIr
lprllpr)F3 mice indicated as BCt (Fig. 1). Approximately
50% of the BCt mice were transgenic (Tr+) and -50%
were nontransgenic (Tr - ). All of the mice were heterozy-
gous for the 1pr gene (Ipr/+). Also, 50%p of the genetic com-
position of these mice are from the MRL strain (50% MRL).
Transgenic (C57BL x MRIrlpr/+)Fi mice were identified
by Southern blot analysis of PvuIl-digested tail DNA hy-
bridized with a probe for Va3 andJs2 (Fig. 2). The TCR-ol
and -# chain transgenes integrated at the same locus in the
transgenic mice and therefore are nearly always inherited to-
gether as shown in Fig. 2. Transgenic BC3 mice were back-
crossed again with MRIrlpr/lpr mice resulting in transgenic
and nontransgenic MR rlpr/lpr and MRIrlpr/+ mice (Fig.
1). An identical breeding scheme was followed to produce
transgenic C57BL/6-1pr/lpr mice. Surprisingly, although mas-
sive lymphadenopathy developed in apprpximately halfof the
nontransgenic mice (five of nine MRL Tr- ; three of six
C57BL/6 Tr-), none of the TCR transgenic litter mates de-
veloped lymphadenopathy (Table 1). Likewise, the same non-
transgenic mice that developed lymphadenopathy also ex-
hibited high levels of circulating CD4-CD8-13220+ T cells,
whereas none of the transgenic mice developed CD4-CD8 -
B220+ T cells. Serum levels of IgG2a anti-dsDNA anti-
bodies were elevated in transgenic MRL mice T36, T41, and
T44 and transgenic C57BL/6 mice T52 and T57, but were
nearly absent in other transgenic mice (Table 1). The elevated
levels of anti-dsDNA autoantibodies correlated with higher
IgG2a RF productionand serum Ig levels in transgenic MRL
1
25% (+/+, Irl+) nl LN
25% (+/+, Ipr/Ipr) fLNFigure 2.
￿
Identification ofTCRtransgenicmiceby analysis of tailDNA. 10 ugof tailDNAfrom backcrossed mice was digested with PvuII restriction
enzyme and analyzed by Southern blot analysis with probes for Va3 andJ02 which hybridize to both transgenic and endogenous DNA. The Va3
probe hybridized to a6.0-kb endogenous band in all mice, but also to transgenic DNAbands at 9.0, 7.0, and 5.0 kb. TheJ02 probe hybridized to
a 5.5-kb endogenous band in all mice, but also to a transgenicDNAband at 7.7 kb. The eartag number of transgenic mice is shown above the figures .
' Transgenic (T) and nontransgenic (NT) mice were evaluated at 14-16 wk of age . Transgenic and nontransgenic C57BL/6 mice were evaluated
at 16-18 wk of age . Results of analysis of transgenic mice are listed separately. Results of analysis of nontransgenic littermate mice are presented
for comparison . The data from different groups of nontransgenic mice (differing in lpr and sex) were combined to determine the mean. n, number ofmice .
t Abbreviations used in the table : Strain used for backcross to TCR transgenic mouse : MRL = MRL/Mpj-lpr/lpr, C57BL/6J-lpr/lpr. Sex: M =
Male, F = Female . lpr : 1/1 = lpr/lpr homozygous mice, 1/+ = lpr/+ heterozygous mice . Distinction of Ipr/lpr from lpr/+ mice was determined
as described in the text . H-2 determined by flow cytometry analysis ofPBMC or spleen cells for expression of I-Ak or I-Ab .
S Mean weight of 2 auxillary and 2 inguinal LN per mouse .
11 Percent of LN cells that are Thy 1+ and B220+ .
I Serum anti-dsDNA and RF levels were determined by ELISA and expressed as OD at 405 run .
"' Serum Ig levels measured by an isotype-specific ELISA including isotype standards of known concentration .
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Table 1 . Phenotype of TCR Transgenic and Nontransgenic Mice Backcrossed with lpr/lpr Mice
Anti-dsDNAI RF 1 Ig's"
Tr" n" T Strain$ Sex# lprt H-2x PLNS B22000 IgM IgG2a IgM IgG2, IgM IgG, IgG2,
mg % mg/ml mg/ml mg/ml
T36 1 + MRL M 1/1 k/k 12 4.0 0.26 0.81 0.15 0.40 0.93 5.5 5.8
T37 1 + MRL M 1/+ b/k 8 1 .0 0.00 0.00 0.09 0.05 0.06 0 .8 0.35
T38 1 + MRL F 1/+ b/k 9 2 .0 0.00 0.03 0.00 0.00 0.10 0.6 0.65
T41 1 + MRL F 1/1 k/k 15 2.0 0.05 0.18 0.12 0.25 0.47 3.1 2.17
T42 1 + MRL F 1/+ b/k 13 0.1 0.00 0.02 0.06 0.07 0.09 0.4 0.59
T44 1 + MRL F 1/1 b/k 16 1 .5 0.54 0.34 0.20 0.53 0.72 4.8 5.3
T50 1 + MRL M 1/+ b/k 15 0.1 0.00 0.00 0.01 0.05 0.08 0.5 0.59
NT 2 - MRL M 1/1 k/k 350 65.0 0.64 0.36 0.10 0.38 0.72 6.0 5.1
NT 3 - MRL F 1/1 k/k 450 70.0 0.44 0.65 0.22 0.42 1 .08 5.8 5.9
NT 2 - MRL M l/+ k/k 13 3 .0 0.05 0.03 0.01 0.05 0.10 0.8 0.8
NT 2 - MRL F 1/+ k/k 15 4.0 0.03 0.03 0.00 0.07 0.10 0.9 0.7
T52 1 + C57BL/6 M 1/1 b/b 17 1.0 0.05 0.12 0.32 1.10 1.80 2.0 4.4
T53 1 + C57BL/6 F 1/+ b/b 15 1.0 0.01 0.06 0.06 0.07 0 .15 1.6 1 .3
T54 1 + C57BL/6 F 1/+ b/b 14 2.0 0.00 0.01 0 .04 0.08 0 .08 2.2 2.6
T57 1 + C57BL/6 F 1/1 b/b 16 4.0 0.05 0.31 0.30 0.25 1.40 0.6 1 .2
T59 1 + C57BL/6 F 1/1 b/b 13 1.0 0.01 0.05 0.07 0 .34 0.16 2.5 4.6
NT 2 - C57BL/6 M 1/1 b/b 260 38.0 0.11 0.36 0.26 0.44 1.20 2.2 4.3
NT 2 - C57BL/6 F 1/1 b/b 310 45.0 0.15 0.43 0.45 0.38 1.50 2.6 4.2
NT 1 - C57BL/6 M 1/+ b/b 16 3.0 0 .06 0.02 0.05 0.09 0.06 0.9 0.1
NT 1 - C57BL/6 F l/+ b/b 15 4.0 0.02 0.01 0.07 0.03 0.08 0.1 0.1Table 2.
￿
Incidence of lpr/lpr Phenotype in Offsprings from 3rd Backcross Mice`
"Offspring data from 5 individual transgenic 2nd backcross parent mice after mating with MRL-lpr/lpr or C57BL/6-lpr/lprmice. Offspring of MRL
mice were evaluated at 14-16 wk of age and offspring of C57BL/6-lpr/lpr mice were evaluated at 16-18 wk of age.
t Results of the analysis of offsprings from single parent were grouped according to presence of the transgene or sex. Approximately 50% ofoffspring
mice expressed both the TCR-a and -0 chain which were always inherited together in these mating. n, number of mice per group.
sLN weight, percent B220+ T cells, anti-dsDNA, RF, and serum Ig levels were determined as in Table 1. The number of mice with elevated
values for each parameter was defined as being 2 SD above the mean, for age, sex, and strain-matched nontransgenic Ipr/ + heterozygous mice.
and C57BL/6 mice (Table 1). Although the autoantibody
and Ig data suggestedthat the lpr gene was present in homozy-
gous form in -50% of the transgenic mice, the absence of
lymphadenopathy and CD4-CD8- B220+ T cells was un-
usual and necessitated further breeding analysis.
To clearly document the existence of TCR transgenic lpr/lpr
mice, parents T36, T37, T44, T50, and T52 were placed in
separate cages, and backcrossed again with MRLlprllpr or,
for T52, with C57BL/6-lpr/lpr mice (Fig. 1) . The presence
ofthe lpr gene in homozygous form in the parents could then
be verified after assessment of their nontransgenic offspring
for development of lymphadenopathy, CD4-CD8-B220+
T cells, and autoantibodies. Analysis of mice from this third
backcross confirmed that T36, T44, and T52 parental mice
were homozygous for the lpr gene and T37 and T50 parental
mice were heterozygous for the lpr gene (Table 2). All non-
transgenic offspring of T36, T44, and T52 parents developed
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lymphadenopathy, elevated anti-DNA and RF titers, and
elevated serum levels of Ig (Table 2). Approximately 50%
of the nontransgenic offsprings of T37 and T50 developed
lymphadenopathy, elevated anti-DNA, and elevated RF as
expected if the TCR transgenic parents were heterozygous
for the lpr gene. Thus, although none ofthe transgenic parents
developed lymphadenopathy, the presence of the lpr gene in
homozygous form couldbe detected by analysis of transgenic
negative offspring. Serum levels of anti-dsDNA were not
effected by the presence of the transgene, but were positive
in 70-80% oflpr/Ipr mice as expected for 10-14-wk-old mice.
Serum levels of RF and Igs were higher in transgenic
C57BL/6-lpr/lpr backcross mice. All transgenic mice and con-
trols used for analysis in this study were genetically at least
87.5% MRL or 87.5% C57BL/6 and will be referred to as
MRL or C57BL/6, respectively. The development oflymph-
adenopathy, without exception, in 100% (47 mice) of non-
Transgenic
parent
Strain lpr
Mating
partner
Strain Ipr
Trans-
genet Sex$ nt
Lymphade-
nopathys
B220S
T cells
Anti
dsDNAS
IgM IgG2a
RFS
I g M IgG2a IgM
Ig'sS
IgGI IgG2a
T36 MRL 1/1 MRL 1/1 + M 8 0/8 0/6 3/6 5/6 1/6 5/6 2/6 6/6 6/6
- M 8 8/8 6/6 6/6 6/6 1/6 5/6 nd 6/6 6/6
+ F 8 0/8 0/6 3/4 3/4 2/4 3/4 nd 4/4 4/4
- F 8 8/8 8/8 7/7 7/7 3/7 7/7 2/2 6/6 6/6
T44 MRL 1/1 MRL 1/1 + M 15 0/15 0/6 5/12 8/12 5/12 10/12 5/5 12/12 12/12
- M 7 7/7 4/4 6/7 6/7 3/7 7/7 5/5 7/7 7/7
+ F 7 0/7 0/5 4/7 3/7 3/7 6/7 2/2 7/7 7/7
- F 8 8/8 5/5 8/8 6/8 5/8 8/8 1/1 8/8 8/8
T52 C57BL/6 1/1 C57BL/6 1/1 + M 6 0/6 0/6 4/6 4/6 6/6 6/6 6/6 6/6 6/6
- M 4 4/4 4/4 3/4 3/4 3/4 3/4 4/4 4/4 4/4
+ F 7 0/7 0/7 5/7 5/7 5/7 5/7 7/7 7/7 7/7
- F 12 8/8 8/8 8/12 8/12 10/12 10/12 12/12 12/12 12/12
T37 MRL 1/+ MRL 1/1 + M 10 0/10 0/10 6/10 6/10 8/10 8/10 8/10 8/10 8/10
- M 6 4/6 4/6 3/6 3/6 5/6 5/6 5/6 5/6 5/6
+ F 7 0/7 0/7 4/7 4/7 5/7 5/7 5/7 5/7 5/7
- F 5 3/5 3/5 3/5 3/5 4/5 4/5 4/5 4/5 4/5
T50 MRL 1/+ MRL 1/1 + M 12 0/12 0/3 7/12 6/12 8/12 6/12 7/12 6/12 6/12
- M 14 8/14 2/3 7/14 8/14 8/14 8/14 7/14 8/14 8/14
+ F 3 0/3 0/3 2/3 2/3 2/3 1/3 2/3 1/3 1/3
- F 10 6/10 2/3 5/10 6/10 5/10 7/10 6/10 6/10 7/10transgenic offspring ofTCR transgenic Ipr/Ipr mice indicated
that the genetic predisposition for development of lym-
phoproliferative disease was not disturbed by the backcross
of TCR transgenic mice with lpr/Ipr mice. The disappear-
ance of lymphadenopathy and CD4 -CD8 -B220+ T cells,
again without exception, in 100% (51 mice) of the TCR
transgenic litter mates, indicated that the inheritance of the
transgenic TCR prevented development of the lymphoprolifer-
ative disease and development of the CD4-CD8-B220+ T
cells.
Elimination of Lymphadenopathy Does Not Require Specific
'ICCR Recognition ofDb MY Antigen. Lymphadenopathy in
MRIrlpr/Ipr and C57BL/6-Ipr/Ipr mice has been proposed
to be due to expansion of self-reactive T cells (3). This would
predict that Db-expressing transgenic male mice would have
increased lymphadenopathy compared with Db-expressing
female mice or with Dk-expressing male or female mice. Al-
ternatively, lymphadenopathy has been proposed to result from
an intrinsic T cell growth abnormally unrelated to the TCR
specificity (25-26). This would predict that replacement of
endogenous TCR gene expression with expression of a trans-
genic TCR gene would have no effect on the intrinsic growth
abnormality and lymphadenopathy in MRIrlpr/Ipr mice.
Therefore, the effect of sex and H-2 on development of
lymphadenopathy and on development of the CD4 -CD8-
B220+ T cells was examined in TCR transgenic mice (Table
3) . Unexpectedly, neither male nor female TCR transgenic
mice developed lymphadenopathy, regardless of expression
of Dk or Db in the thymus or LN of these mice. Nontrans-
genic lpr/lpr litter mates developed enlarged LN as expected
(Table 3). Therefore, the presence of the Db-restricted
H-Y-reactive transgenic TCR resulted in elimination of lymph-
adenopathy independent of expression of the Db and male
H-Y antigen, suggesting the specificity of the transgenic TCR
was not playing a critical role in the reduction oflymphade-
nopathy.
Reduction in Dull Thri, B220+ T Cells in the Thymus and
LN ofTCR Transgenic MRI Ipr/lpr Mice. To determine the
effect of the TCR transgene on production of the abnormal
T cells in MRIrlpr/lpr and C57BL/6-Ipr/Iprmice, simultaneous
' Data from 100 mice divided into 20 groups of mice differing in strain (MRL = 87.5% MRL/Mpj; C57BL/6 = 87.5% C57BL/6J), transgene
expression, H-2 (b/k = H-2bik; k/k - H-2k/k; b/b = H-2b/b), and sex (M = male, F = female).
t n, number of mice in each group.
S LN weight and the percent of Thy 1+,B220+ cells (B220+ T cells) were determined as in Table 1. The total number of thymocytes was deter-
mined on each mouse after sacrifice and preparation of thymocyte cell suspensions.
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Table 3. Effect of TCR Transgene on LN, 6B2 T Cells, and Total Thymocytes
Strain" lpr' Transgene" H-2" Sex` nt LNS B220+ T celss Thymocytes
mg % (x 10-6)
MRL lpr/lpr + b/k M 5 13.1±2 .3 4.1±1 .4 60±10
+ b/k F 5 15.2 ± 2.8 3.2 ± 0.9 133 ± 12
+ k/k M 5 14.0 ± 1.4 3.1 ± 1.8 33 ± 6
+ k/k F 5 14.1±3.5 3.6±2.6 47±11
- k/k M 5 450.0 ± 56 71 . ± 10 128 ± 10
- k/k F 5 514.0 ± 58 77 . ± 10 141 t 17
MRL +/+ + b/k M 5 9.2 ± 3.2 3.6 ± 2.6 16 ± 5
+ b/k F 5 10.1 ± 1.4 3.8 ± 0.7 93 ± 12
+ k/k M 5 10.2 ± 1.4 3.8 ± 1.6 57 ± 8
+ k/k F 5 10.4 ± 1.7 3.8 ± 1.2 34 ± 7
- k/k M 5 1.1 ± 2.4 4.2 ± 1.6 103 ± 5
- k/k F 5 9.6 ± 2.1 3.4 ± 0.8 108 ± 9
C57BL/6 Ipr/lpr + b/b M 5 8.4 ± 1.9 3.2 ± 1.7 16 ± 3
+ b/b F 5 8.2±2.6 3.2±0.7 123±10
- b/b M 5 228. ± 50 44. ± 9 108 ± 13
- b/b F 5 285. ± 44 54. ± 8 119 ± 12
C57BL/6 +/+ + b/b M 5 5.6 ± 2.6 3.4 ± 1.9 8 ± 2
+ b/b F 5 6.1 ± 1.1 3.4 ± 1.5 99 ± 8
- b/b M 5 7.2 t 1.4 3.4 ± 1.9 101 ± 12
- b/b F 5 7.4 ± 0.9 3.2 ± 1.2 104 ± 7analysis of expression of Thy-1, CD4, and B220 (detected
by antibody clone6B2) was carried out by three-color flow
cytometry analysis. Figs. 3 and 4 illustrate the flow cytom-
etry analysis for H-26n female MRIJIpr/lpr mice, while the
percent of B220+ T cells for other strains of mice is sum-
marized in Table 3. The intensity ofThy-1 was gated on LN
T cell populations that were Thy-1 negative (gate A), Thy-1
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Figure 3.
￿
Expression of Thy-1, CD4, and B220 (detected by antibody
clone 6B2) on LN cells from nontransgenic and TCR transgenic H-2tik
female MRblpr/lpr mice. Peripheral LN cells were analyzed by three-color
flow cytometry analysis (10,000 events). The intensity ofThy-1 expression
was gated on Thy-l-negative (gate A), Thy-1 dull (gate B), and Thy-1
bright (gate C as shown in the top panels of the figures. Gate B was
chosen to include primarily the abnormal dull Thy-1 B220+ T cells
present in the LN and thymus of MRIrlpr/lpr mice. For each Thy-1 gate,
the contour plot of CD4 vs. B220 is displayed. The percent of total cells
in each population is shown.
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￿
Expression of Thy 1, CD4, and B220 on thymocytes from
nontransgenic and TCR transgenic H-26ik female MR1r1pr/lpr mice. Flow
cytometry analysis was carried out as described for Fig. 3.
dull (gate B) or Thy-1 bright (gate C) (Fig. 3, top). In non-
transgenic MR1Jlpr/lpr mice, the Thy-1-negative population
of LN cells was B220+CD4 - CD8 - as expected for B cells
(Fig. 3, A). The dull Thy-1 population was predominantly
abnormal B220+ T cells but also contained some
B220+CD4+ T cells (13, 27) (Fig. 3, B). In TCR transgenic
MRIrlpr/Ipr mice, the intensity profile of Thy-1 on LN T
cells had an increase in Thy-l-negative and bright Thy-1 lym-
phocytes, and a decrease in dull Thy-1 lymphocytes. There
was an increase in percentage of normal numbers of Thy-
1 -B220+ cells, no detectable dull Thy-1 B220+ T cells, and
3%
4% 11%
16%
8% 8%
1%
2% 28%
11% 2%'
504
2%
2% 10%'
3% 44%
10% 1%an increased percentage of mature bright Thy-1 CD4+ or
CD4' T cells (Fig. 3, A-C) .
It is possible that abnormal B220+ T cells could be
present in the thymus ofTCR transgenic MR1r1pr/lpr mice
as reported for nontransgenic MRIrlpr/lpr mice, but not be
detected in peripheral lymphoid organs . The histogram of
Thy-1 for nontransgenic MRLIpr/1pr thymocytes revealed a
small dull Thy-1 population (Fig. 4, top) . These were not
due to contaminating encroachingLN because histologic sec-
tions of this thymus demonstrated the presence of B220+
cells within the thymus and the absence of perithymic lym-
phoid tissue (28) (data not shown) . The Thy-l-negative
thymocytes were predominantly B220+ . This is consistent
with previous reports ofB cells within the thymus of au-
toimmune strains of mice (29) . The dull Thy-1 population
contained substantial numbers of B220+ T cells, and also
B220 - normal thymocytes, which were predominantly
CD4+ (CD4+,CD8+) . Only normal thymocytes were found
in the bright Thy-1 population (Fig. 4, C) . TCR transgenic
MR1rlpr/1pr mice contained predominantly a single bright
Thy-1 population of thymocytes (Fig. 4, top) . The Thy-1-nega-
tive population is B220+ and indistinguishable from B cells
found in theLN, suggesting that the transgene does not re-
sult in a reduction ofB cells in the thymus of MRIrlpr/lpr
mice . Less than 1% of the dull Thy-1 population of thymo-
cytes were B220+ T cells. Bright Thy-1 thymocytes in trans-
genic MRIrlpr/1pr mice contained no B220+ thymocytes. In
addition, there were increased numbers of CD4-B220 -
bright Thy-1 thymocytes . These results suggest that the trans-
gene greatly reduces or eliminates development of the dull
Thy-1 B220+ T cells in theLN, and thymus of MR1rlpr/lpr
mice. The percent ofB220+Thy 1+ abnormal T cells in LN
of lprllpr, and +/+ mice differing in strain, transgene ex-
pression, H-2, and sex is summarized in Table 3 .
Reduction ofLymphadenopathy Is Not Due to Lack ofT Cell
Maturation in the Thymus. The cellular basis underlying de-
velopment oflymphadenopathy in lprllpr mice has been pro-
posed to be due to release of excessive numbers of autoreac-
tive T cells from the thymus to the LN (2, 3) . One possible
explanation for a decrease in lymphadenopathy would be that
theTCR transgenic lpr/lpr micemay have a decrease in produc-
tion of mature thymocytes leading to a decrease in lymphad-
enopathy . This effect might be especially important in H-2Db-
expressing male mice, because the majority of thymocytes
express the transgenic TCR and therefore these self-reactive
T cells could be eliminated in the thymus by a negative selec-
tion process. To investigate the overall effect ofthe TCR trans-
gene on thymocyte development, the totalnumber of thymo-
cytes was determined in 20 groups ofmice differing in strain,
transgene expression, H-2, and sex (Table 3) . There was an
increase in the number of total thymocytes in nontransgenic
MRlrlpr/lpr and C57BL/6-1pr/lpr mice compared with non-
transgenic MRL +/+ and C57BL/6 +/+ mice as previ-
ously described (28) . There were high numbers of thymo-
cytes in both transgenic MRlrlpr/lpr andMRL +/+ Dbik
female mice. This is consistent with the presence of a high
rate of positive selection on Db thymic epithelial cells, and
also a low rate of negative selection due to the absence of
the male antigen . In contrast, there is a dramatic decrease
in the total number of thymocytes in transgenic MRL +/+
Db/k male mice to 15% of that observed in a normal thymus
consistent with a high rate of positive selection and also a
high rate ofnegative selection due to the presence ofthe male
H-Y antigen. However, in transgenic MRIrlpr/lpr Db/k male
mice, there was only a 50% decrease in the total number
of thymocytes, compared with nontransgenic MR1r1pr/lpr
mice or transgenic Db/k female MRIrlpr/lpr mice . This sug-
gests that selection events in the thymus of MRlrlpr/lpr mice
are significantly altered compared to MRL +/+ mice. The
thymus of Dk/k male and female transgenic mice are reduced
to between one third and one half of normal size . This is
consistent with the lack of efficient positive and negative se-
lection of transgene-expressing T cells on Dk1k thymic cells.
In transgenic C57BL/6-lpr/lpr and C57BL/6 +/+ female
mice, there were nearly normal numbers of thymocytes as
described above for MRL Db/k female mice. There was a
dramatic reduction in total numbers of thymocytes in trans-
genic C57BL/6-lpr/lpr andC57BL/6 +/+ male mice. How-
ever, there was a twofold increase in the number of thymo-
cytes in transgenic C57BL/6-lpr/lpr males compared with
transgenic C57BL/6 +/+ males, again suggesting an altered
selection process in lprllpr mice compared with +/+ mice.
These data indicate that although the H-2Db-expressing
TCR transgenic lprllpr male mice have a decrease in number
of thymocytes, these were increased in numbers compared
with male +/+ mice . Also, transgenic Dbnb and Dblk female
mice had normal numbers ofthymocytes compared with non-
transgenic mice. Therefore, elimination of lymphadenopathy
in female lprllpr mice could not be solely attributed to nega-
tive selection in the thymus .
T CellsfromLNofTCR Transgenic lpr/1prMice Can Proliferate
In Vitra Development of lymphadenopathy in lprllpr mice
has been proposed to result from proliferation of self-reactive
Figure 5.
￿
SMLR proliferative response to transgenic and nontransgenic
lprllpr and lpr/+ mice. Spleen cells (106) were cultured for 5 d at 37°C
in 5% C02 . During the last 6 h of culture, 1 yCi [3H]thymidine was
added and proliferation was measured as [3H]thymidine uptake. The value
shown is the mean ± SEM for the average oftriplicate cultures performed
using 2-4 individual mice per group. H-2k/k and H-2eik mice were from
the MRL strain . H-2b/b mice were from the C57BL/6 strain .
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the inhibition of lymphadenopathy in the TCR transgenic
Ipr/lpr mice might be that there was a loss of self-reactive
LN T cells in TCR transgenic mice. Although early, high
expression of the transgenic TCR is known to occur in the
thymus (16), these cells might be efficiently eliminated by
negative selection in the thymus in both +/+ and lprllpr
mice expressing the Db and H-Y antigen. Alternatively, in
lprllpr mice not expressing the Db and H-Y antigen, produc-
tion oflarge numbers ofmature T cells expressing the trans-
genic TCR might inhibit production of T cells capable of
reacting with self. Therefore, to determine ifLN T cells from
TCR transgenic lprllpr mice contain cells capable of self-
stimulation, syngeneic mixed lymphocyte reaction (SMLR)
analyses were performed (Fig. 5). There was a dramatic in-
crease in the SMLR proliferative potential of T cells from
TCR transgenic C57BL/6-Ipr/Ipr male and female Db/b mice
compared to TCR transgenic C57BL/6-Ipr/+ mice. These
results suggest that autoreactive T cells are present in the
LN ofC57BL/6-Ipr/Ipr mice. There was no significant change
in the SMLR proliferative potential of T cells from TCR
transgenic MRLIpr/Ipr male or female Dk/k or Db/k mice
compared with control TCR transgenic MRLIpr/+ mice or
nontransgenic mice. This was not simply due to the absence
of Db/b male stimulator cells because there was also no
significant difference in the proliferative responses of T cells
from these mice after culture with irradiated Db/b male
stimulator cells (datanot shown). Therefore, although it could
be argued that in lprllpr Dk1k and DI/k mice, lymphadenop-
athy is eliminated because there is no self-stimulation, this
is not true for C57B1/6-Ipr/Ipr mice as there were numerous
T cells capable of responding in vitro to self-antigen. These
data also suggest that a suppression mechanism is present in
C57BL/6-lpr/lpr mice in vivo that is released by in vitro
culture.
Elevated Autoantibody andIg Production Occur Independently
of Lymphadenopathy. The presence of the TCR transgene
completelyinhibited the lymphadenopathy and the develop-
ment of CD4 - CD8 - B220+ T cells in lprllpr mice. How-
ever, the data from the lpr1lpr and lpr1+ backcross mice sug-
gested that the transgenic lprllpr mice still developed elevated
levels of anti-DNA autoantibodies, RF, and Ig (Tables 1 and
2). To determine the effects of the TCR transgene on au-
toantibodyproduction, and to verify that autoantibody pro-
duction and hypergammaglobulinemia could be dissociated
from lymphadenopathy, serum antibody levels in TCR trans-
genic lprllpr mice were compared with nontransgenic lprllpr
mice (Table 4). There was no significant difference in serum
levels of IgM and IgG2a anti-dsDNA antibodies in TCR trans-
genic MRLIpr/Ipr mice compared with nontransgenic MRL
lprllpr mice. Nontransgenic C57BL/6-Ipr/Iprmice had lower
levels of IgM and IgG2a anti-dsDNA compared with non-
transgenic MRLlprllpr mice as previously reported (4), but
there was no difference between TCR transgenic C57BL/6-
lprllpr mice and nontransgenic C57BL/6-Ipr/lpr mice.
Serum levels of IgM and IgG2a RF were elevated in 12-16-
wk-old transgenic and nontransgenic MRLIpr/Iprmice com-
pared with transgenic and nontransgenic MRL +/+ mice
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(Table 4). There was a significant increase in the IgM RF
levels in the TCR transgenic Db/k male MRL1pr/lpr mice
compared with the TCR transgenic Db/k female MRL
lpr/Ipr mice (p < 0.05). The higher levels of RF were not
observed in the TCR transgenic H-2Dkik male mice; there-
fore the expression of H-2Db was also required. Serum levels
of RF were elevated in 12-16-wk-old transgenic and non-
transgenic C57BL/6-lpr/lpr mice compared with transgenic
and nontransgenic C57BL/6 +/+ mice. There was a sig-
nificant increase in IgM and IgG2a RF level in transgenic
Db5 male C57BL/6-Ipr/lpr compared with nontransgenic
male C57BL/6-Ipr/Ipr mice (p < 0.05). Serum levels of im-
munoglobulins of the IgG1 and IgG2a isotype were sig-
nificantlyhigher in nontransgenic lpr/l pr mice compared with
nontransgenic +/+ mice, consistent with previous observa-
tions (4). The serum level of IgG1 was significantly higher
in transgenic Db/b C57BL/6-Ipr/Ipr male mice compared
with nontransgenic Db/b C57BL/6-Ipr/lpr male mice (p <
0.05). These results indicate that although the transgene
resulted in the elimination of lymphadenopathy and forma-
tion of CD4-CD8 -B220+ T cells, high levels of anti-
DNA, RF, and Ig's persist in transgenic lprllpr mice. These
results are in agreement with previous data suggesting that
lymphadenopathy can be dissociated from hypergam-
maglobulinemia and autoantibody production in MRLIpr/lpr
and C57BL/6-Ipr/Iprmice (24, 35). Moreover, these data also
suggest that the transgene can enhance RF and Ig produc-
tion in lprllpr mice in the presence of both the H-2Db an-
tigen and the male antigen. Thus, recognition of the Db +
H-Y antigen by the transgenic TCR plays a role in augmen-
tation of RF and IgG1 production.
The cellular and molecular basis for overproduction of the
CD4 -CD8 - B220+ T cells in the LN of lprllpr mice is'un-
known. Neonatal thymectomy inhibits development oflym~h-
adenopathy (9, 10), and partial inhibition is evident if the
mice are thymectomized before 3 wk of age (9). This has
led to the conclusion that T cells that develop in and leave
the thymus during the first 3 wk of life migrate to the pe-
riphery and lead to lymphadenopathy. It has been difficult
to separate the contribution of autostimulation resulting in
peripheral expansion of T cells in LN of lprllpr mice from
an endogenous T cell maturation defect leading to lymphad-
enopathy without stimulation through the TCR (25, 30-32).
The total suppression oflymphadenopathy in the TCR trans-
genic lprllpr mice provides further insight into this question.
The presence of the TCR transgene results in early, high levels
of expression ofthe TCR in thymocytes (16). The transgenic
TCR that recognizes H-2Db and the male HY antigen is ex-
pressed on nearly 100% ofimmature thymocytes. Therefore,
in H-2Db male lpr/lpr mice, there is production of large
numbers ofimmature thymocytes which are autoreactive. In
H-2k/k or female lprllpr mice, the TCR is not autoreactive.
Also in H-2Db mice, there is a high probability that the
TCR transgene-expressing T cells will undergo positive se-
lection whereas in Dk/k mice, positive selection of transgenictt
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different positive and negative selection events that occur in
the lprllpr strains of mice studied, none of the transgenic
mice developed lymphadenopathy or detectable numbers of
CD4-CD8-B220+ T cells. Therefore, we propose that the
presence of early, high expression of the transgenic TCR,
independent ofspecificity or thymic selection, leads to elimi-
nation oflymphadenopathy and autoimmunity. The mecha-
nism for this will be discussed in terms oftwo different models
proposed to explain the generation of CD4-CD8- B220+
T cells in lprllpr mice.
The first model for generation of CD4-CD8'B220 + T
cells suggests that an abnormal positive selection process in
the thymus of the lprllpr mice results in massive lymphade-
nopathy (36). The data presented herein support and shed
new light onto this model. The observation that T cells ex-
pressing self-reactive (Mls or MHC-reactive) V,6 regions are
deleted from the CD4 - CD8 -B220+ LN T cells (11-13) and
also from both the CD4+ and CD8+ single positive LN T
cells in lprllpr mice (36) led to the suggestion that the
CD4-CD8-B220+ T cells are derived from a CD4+CD8+
precursor by abnormal positive selection (36). We have re-
cently observed that in H-2Db- and HYreactive TCR
transgenic mice, there is an overefficient positive selection pro-
cess in lprllpr mice compared to +/+ mice resulting in deple-
tion of the CD4+CD8+ thymocytes subpopulation and ex-
pansion of CD4+ and CD8+ single-positive thymocytes. (T
Zhou, H. Bluthmann, andJ. D. Mountz, manuscript in prep-
aration). This aberrant positive selection has been proposed
to result in active downregulation of CD4 and CD8 and
production of CD4- CD8' T cells which leave the thymus
and migrate to the periphery (11-13, 36). Furthermore, since
these CD4-CD8 - T cells are the result of a positive selec-
tion process, they would be expected to be skewed towards
reactivity with MHC, as observed in lprllpr mice (30-32).
The mechanism behind the proposed aberrant positive selec-
tion in the thymus of lprllpr mice is not known, but may
be related to a maturational defect resulting in low expres-
sion of TCR and CD3 as observed on the CD4-
CD8- B220+ in the LN of lprllpr mice (37). The presence
of the TCR transgene might overcome this maturational de-
fect by allowing the cells to express high levels of the TCR
and CD3. This would also suggest that a defect of TCR ex-
pression might represent an intrinsic thymic maturational ab-
normality of T cells in lprllpr mice.
The second model for generation of CD4 -CD8 - B220+
T cells suggest that an intrinsic T cell defect, which may
require the lprllpr internal milieu, results in massive lymph-
adenopathy (25, 26). This model is not supported by the
demonstration that a transgenic TCR can eliminate lymph-
adenopathy. A number ofdefects have been identifiedin lprllpr
mice including abnormal phosphorylation of the tyrosine
residues of membrane proteins (38), rapid TCR and CD3
modulation (39), altered K+ channel expression (40), aber-
rant arachidonic acid turnover in T cell membranes (41), and
enhanced or altered regulation of c-myb, c-raf, and c-my~ on-
cogenes (42). The mechanism by which one or more ofthese
defects could lead to production of CD4-CD8 -B220+ T
cells is not known, but all of these defects have been related
to altered states of T cell activation. For example, phosphor),
lation of the TCR/CD3-tchain is associated with T cell ac-
tivation, and constitutive phosphorylation might be an aber-
ration of this process. The transgenic TCR would induce
early high levels of TCR expression in the thymus of lprllpr
mice. It is unlikely that TCR transgene expression could
directly reverse a primary defect in any of the metabolic
pathways which have been associated with the CD4 - CD8 -
B220+ T cells of lpr mice. It is possible, but still unlikely,
that the rearranged TCR transgene and early TCR expres-
sion could indirectly inhibit one of these metabolic events.
For example, if constitutive phosphorylation of the TCR/
CD3-r chain was a fundamental defect leading to lympho-
proliferation (37), this defect should still be present despite
the presence of a rearranged TCR transgene. Therefore, we
conclude that the metabolic defects described above result
from a more fundamental T cell maturationabnormality that
can be corrected in the TCR transgenic mice. A note ofcau-
tion is required in this interpretation because these previously
described metabolic abnormalities have not yet been measured
in the LN T cells of TCR transgenic lprllpr mice.
Several treatment schemes have been used to reduce the
lymphoproliferative disease and autoimmune disease in MRls
lprllpr mice. Treatment with cyclophosphamide affected both
B cell and T cell development resulting in reduction oflymph-
adenopathy, autoantibody production, and autoimmune
disease (43). Treatment with cyclosporine A reduced lymphade-
nopathy and autoimmunity by interfering with T cell signal-
ing, but did not reduce autoantibody production (24). Treat-
ment with Mel 14 prevented lymphadenopathy by blocking
peripheral LN homing ofT cells, but did not reduce autoanti-
bodies (35). In the present study, the presence of a rearranged
transgenic TCR gene completely inhibited development of
lymphadenopathy and formation of CD4 - CD8-B220+ cells
in 1pr11pr mice. In H-2k/k mice, there was no significant dif-
ference in hypergammaglobulinemia or autoantibody produc-
tion between transgenic and nontransgenic lprllpr mice. In
male H-2b/k and H-Vb lprllpr mice, there was an increase
in Ig and RF productioncompared with nontransgenic lprllpr
mice. These results support previous findings that the lym-
phoproliferation disease and autoantibody production in lprllpr
mice can be dissociated.
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